You are here: Industry Insights > Paxlovid

News List

FDA Authorizes First Oral Antiviral for Treatment of COVID-19 WorldPharmaNews
December 23, 2021
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer's Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease...
Pfizer to provide UK with additional 2.5 treatment courses of Paxlovid pharmatimes
December 22, 2021
With authorisation, Pfizer’s oral antiviral candidate Paxlovid is an investigational SARS-CoV-2 protease inhibitor could be prescribed at the first sign of COVID-19 infection.
FDA Approves Pfizer Pill as First At-Home COVID-19 Treatment drugs
December 22, 2021
The U.S. Food and Drug Administration on Wednesday approved the emergency use of the new Pfizer antiviral pill Paxlovid in people who are at high risk for severe COVID-19.
FDA Grants Emergency Use Authorization for Pfizer's Paxlovid Pill as First At-Home COVID-19 Treatment drugs
December 22, 2021
he U.S. Food and Drug Administration on Wednesday approved the emergency use of Pfizer's new antiviral pill Paxlovid in people who are at high risk for severe COVID-19. It's the first approved treatment for COVID-19 meant to be taken at home.
Pfizer’s Paxlovid™ can be used for the treatment of COVID-19, says EMA EuropeanPharmaceuticalReview
December 21, 2021
New European Medicines Agency advice states Paxlovid™ can be used to treat those at high risk of developing severe COVID-19 symptoms.
EMA CHMP advises use of Pfizer’s Covid-19 oral antiviral Paxlovid Pharmaceutical-Technology
December 20, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the usage of Pfizer’s oral antiviral, Paxlovid (nirmatrelvir plus ritonavir), to treat adult Covid-19 patients.
Covid-19: Pfizer’s antiviral Paxlovid effective against severe disease and Omicron variant Pharmaceutical-Technology
December 16, 2021
Pfizer has announced that its investigational Covid-19 antiviral, Paxlovid, offers high protection against severe disease from coronavirus and is effective against the new variant Omicron.
Pfizer Says Final Data Show COVID-19 Pill Stays Strong Against Severe Illness Drugs
December 15, 2021
Pfizer Inc. announced Tuesday that a final analysis shows its experimental antiviral pill Paxlovid sharply reduced hospitalizations and deaths among COVID-19 patients at high risk for severe illness.
Pfizer to supply ten million courses of Covid-19 oral antiviral to the US Pharmaceutical-Technology
November 22, 2021
The US Government has signed an agreement with Pfizer to procure ten million courses of the company’s Covid-19 oral antiviral candidate, Paxlovid (PF-07321332; ritonavir)...
Pfizer to provide U.S. government with 10 million treatment courses of investigational oral antiviral candidate to help combat COVID-19 WorldPharmaNews
November 19, 2021
Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID™ (PF-07321332; ritonavir)...

Previous page 1 2 3 4 Next page